Aeglea BioTherapeutics (Pegzilarginase Assets) Overview

  • Status
  • Acquired/​Merged

  • Latest Deal Type
  • Buyout/​LBO

  • Financing Rounds
  • 1

Aeglea BioTherapeutics (Pegzilarginase Assets) General Information

Description

A global rights of pegzilarginase, a novel recombinant enzyme therapy engineered to degrade the amino acid arginine.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Private Equity-Backed
Corporate Office
  • TX
  • United States
Primary Industry
Buildings and Property
Acquirer
Corporate Office
  • TX
  • United States

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Aeglea BioTherapeutics (Pegzilarginase Assets) Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Aeglea BioTherapeutics (Pegzilarginase Assets)‘s full profile, request access.

Request a free trial

Aeglea BioTherapeutics (Pegzilarginase Assets) Former Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Aeglea BioTherapeutics (Pegzilarginase Assets)‘s full profile, request access.

Request a free trial

Aeglea BioTherapeutics (Pegzilarginase Assets) FAQs

  • Where is Aeglea BioTherapeutics (Pegzilarginase Assets) headquartered?

    Aeglea BioTherapeutics (Pegzilarginase Assets) is headquartered in TX.

  • What industry is Aeglea BioTherapeutics (Pegzilarginase Assets) in?

    Aeglea BioTherapeutics (Pegzilarginase Assets)’s primary industry is Buildings and Property.

  • Is Aeglea BioTherapeutics (Pegzilarginase Assets) a private or public company?

    Aeglea BioTherapeutics (Pegzilarginase Assets) is a Private company.

  • What is the current valuation of Aeglea BioTherapeutics (Pegzilarginase Assets)?

    The current valuation of Aeglea BioTherapeutics (Pegzilarginase Assets) is .

  • What is Aeglea BioTherapeutics (Pegzilarginase Assets)’s current revenue?

    The current revenue for Aeglea BioTherapeutics (Pegzilarginase Assets) is .

  • Who are Aeglea BioTherapeutics (Pegzilarginase Assets)’s investors?

    Aeglea BioTherapeutics has invested in Aeglea BioTherapeutics (Pegzilarginase Assets).

  • When was Aeglea BioTherapeutics (Pegzilarginase Assets) acquired?

    Aeglea BioTherapeutics (Pegzilarginase Assets) was acquired on 27-Jul-2023.

  • Who acquired Aeglea BioTherapeutics (Pegzilarginase Assets)?

    Aeglea BioTherapeutics (Pegzilarginase Assets) was acquired by Immedica Pharma.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process